Clinical Trial Update: Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat [Phase 3]

View source ↗

Summary

Phase 3 safety study of ATX-101 (deoxycholic acid) in adults with submental fat completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Submental Fat Excess
• To Severe Convexity of Submental Fat

Drugs mentioned

• ATX-101 (Deoxycholic acid)

Snippet

Sponsor: Kythera Biopharmaceuticals | Conditions: Moderate to Severe Convexity of Submental Fat, Safety | Phase 3 | Status: COMPLETED | Results posted: 2020-02-17